Fortress Biotech Future Growth
Future criteria checks 5/6
Fortress Biotech is forecast to grow earnings and revenue by 55.3% and 37.6% per annum respectively while EPS is expected to grow by 59.8% per annum.
Key information
55.3%
Earnings growth rate
59.8%
EPS growth rate
Biotechs earnings growth | 32.0% |
Revenue growth rate | 37.6% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 20 Dec 2023 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 375 | 123 | -33 | -31 | 1 |
12/31/2025 | 237 | 18 | -76 | -75 | 1 |
12/31/2024 | 176 | 60 | N/A | -189 | 2 |
12/31/2023 | 65 | -101 | N/A | -164 | 2 |
9/30/2023 | 62 | -78 | -150 | -141 | N/A |
6/30/2023 | 63 | -96 | -176 | -168 | N/A |
3/31/2023 | 64 | -92 | -182 | -176 | N/A |
12/31/2022 | 76 | -87 | -202 | -179 | N/A |
9/30/2022 | 78 | -97 | -196 | -170 | N/A |
6/30/2022 | 82 | -93 | -181 | -149 | N/A |
3/31/2022 | 81 | -74 | -179 | -142 | N/A |
12/31/2021 | 69 | -65 | -133 | -117 | N/A |
9/30/2021 | 64 | -38 | -113 | -98 | N/A |
6/30/2021 | 53 | -33 | -110 | -101 | N/A |
3/31/2021 | 44 | -43 | -89 | -83 | N/A |
12/31/2020 | 46 | -47 | -91 | -84 | N/A |
9/30/2020 | 43 | -57 | -99 | -88 | N/A |
6/30/2020 | 43 | -54 | -92 | -81 | N/A |
3/31/2020 | 43 | -54 | -102 | -92 | N/A |
12/31/2019 | 37 | -40 | -104 | -95 | N/A |
9/30/2019 | 34 | -45 | -98 | -92 | N/A |
6/30/2019 | 30 | -51 | -106 | -101 | N/A |
3/31/2019 | 27 | -53 | -105 | -96 | N/A |
12/31/2018 | 27 | -73 | -108 | -99 | N/A |
9/30/2018 | -107 | -61 | -107 | -98 | N/A |
6/30/2018 | -65 | -69 | -105 | -98 | N/A |
3/31/2018 | -22 | -72 | -102 | -98 | N/A |
12/31/2017 | 17 | -65 | -85 | -81 | N/A |
9/30/2017 | 155 | -74 | -82 | -78 | N/A |
6/30/2017 | 109 | -60 | N/A | -62 | N/A |
3/31/2017 | 61 | -55 | N/A | -46 | N/A |
12/31/2016 | 16 | -55 | N/A | -46 | N/A |
9/30/2016 | 4 | -50 | N/A | -35 | N/A |
6/30/2016 | 3 | -55 | N/A | -31 | N/A |
3/31/2016 | 1 | -49 | N/A | -30 | N/A |
12/31/2015 | 1 | -48 | N/A | -20 | N/A |
9/30/2015 | 1 | -40 | N/A | -17 | N/A |
6/30/2015 | 1 | -27 | N/A | -14 | N/A |
3/31/2015 | 1 | -25 | N/A | -12 | N/A |
12/31/2014 | N/A | -20 | N/A | -16 | N/A |
9/30/2014 | N/A | -26 | N/A | -20 | N/A |
6/30/2014 | N/A | -30 | N/A | -24 | N/A |
3/31/2014 | N/A | -36 | N/A | -28 | N/A |
12/31/2013 | N/A | -37 | N/A | -30 | N/A |
9/30/2013 | N/A | -36 | N/A | -30 | N/A |
6/30/2013 | N/A | -34 | N/A | -27 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CNB1 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.5%).
Earnings vs Market: CNB1 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: CNB1 is expected to become profitable in the next 3 years.
Revenue vs Market: CNB1's revenue (37.6% per year) is forecast to grow faster than the German market (4.5% per year).
High Growth Revenue: CNB1's revenue (37.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CNB1's Return on Equity is forecast to be high in 3 years time